Related Experiment Videos
[A clinical study of rokitamycin in pediatrics]
K Sunakawa1, Y Ishizuka, N Saito
1Department of Pediatrics, Second Tokyo National Hospital.
Insights
Rokitamycin (RKM) dry syrup demonstrated high efficacy in treating pediatric infections, with a 95.8% overall clinical response rate. This macrolide antibiotic showed good tolerability, with minimal adverse effects reported in the study.
Area of Science:
- Pharmacology
- Pediatric Infectious Diseases
- Antimicrobial Therapy
Context:
- Pediatric infections pose a significant health challenge, requiring effective and safe treatment options.
- Macrolide antibiotics are commonly used for bacterial infections in children.
- Assessing the efficacy and safety of novel or existing antimicrobial agents in pediatric populations is crucial.
Purpose:
- To evaluate the clinical and bacteriological efficacy of rokitamycin (RKM) dry syrup in pediatric patients with various infections.
- To assess the safety and tolerability profile of RKM dry syrup in this patient group.
Summary:
- A total of 29 pediatric patients received oral rokitamycin (RKM) dry syrup at dosages ranging from 21.4-44.4 mg/kg/day.
- Clinical efficacy was observed in 24 patients across tonsillitis, laryngitis, bronchitis, bronchopneumonia, psittacosis, and Campylobacter colitis, with an overall efficacy rate of 95.8%.
- Bacteriological responses included eradication or reduction of key pathogens such as Streptococcus pyogenes, Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, and Campylobacter spp. Adverse reactions were mild and infrequent, primarily gastrointestinal, with one case of elevated platelet count.
Impact:
- Rokitamycin (RKM) dry syrup shows promise as a safe and effective therapeutic option for a range of pediatric infections.
- The findings support the potential utility of RKM in pediatric infectious disease management.
- Further research may establish RKM as a valuable addition to the pediatric antimicrobial armamentarium.
Abstract:
A total of 29 patients with pediatric infections was treated orally with 21.4-44.4 mg/kg/day of rokitamycin (RKM) dry syrup. The obtained results are summarized as follows. 1. Clinical responses to RKM in 24 evaluable patients were excellent in 2 and good in 3 of 5 patients with tonsillitis and laryngitis; excellent in 3 and good in 5 of 8 patients with bronchitis; excellent in 3, good in 2 and fair in one of 6 patients with bronchopneumonia; excellent in 2 and good in the other of 3 patients with psittacosis; and excellent in 2 of 2 patients with Campylobacter colitis. The overall efficacy rate was 95.8%. 2. Bacteriological responses to the drug were: reduction in 1 and no change in the other of 2 strains of Streptococcus pyogenes; eradication of a strain of Streptococcus pneumoniae and 2 strains of Staphylococcus aureus; eradication of 2 and no change in 3 of 5 strains of Haemophilus influenzae; and eradication of 2 out of 2 strains of Campylobacter spp. 3. Diarrhea was complained of as an adverse reaction to the RKM medication by 1 patient, abdominal pain was reported by another, and anorexia by another of the 27 patients treated. Laboratory examination was performed on some patients, but not abnormal test values were found except in 1 case showing an increase in platelet count from 27.6 to 78.2 X 10(4)/mm8. The results suggested that RKM dry syrup might be a very useful and safe drug for the treatment of pediatric infections.